
NEMLUVIO RELIEVES ITCH FAST WITH SKIN HEALING THAT LASTS
Managing prurigo nodularis (PN) and atopic dermatitis (AD) can be challenging, especially when topical therapies and other treatments fail to provide relief. For patients who struggle with persistent itching, it may be time to consider a different approach.
NEMLUVIO® is an IL-31RA–targeted biologic that delivers itch relief as soon as 48 hours* in some patients, and helps block the urge to scratch, so patients can experience skin healing that lasts. Indicated for the treatment adults and adolescents (aged ≥12 years) with uncontrolled AD despite topicals and adults with PN.1-4
Fast relief. Lasting results. Clinical studies show NEMLUVIO helps patients break the itch cycle and heal their skin. In PN, 49% of patients achieved significant itch relief at Week 16 compared to 16% with placebo (P<0.0001).† Beyond rapid relief, NEMLUVIO is proven to provide lasting itch relief with nearly 2 years of treatment (Week 100). In fact, 94% of patients with PN maintained itch relief after nearly 2 years of treatment.‡ For AD, consistent itch relief was observed across both ARCADIA 1 and ARCADIA 2 trials. Over 2 years of treatment, 82% of patients with AD achieved lasting relief with NEMLUVIO combined with TCS/TCI.1-9§
NEMLUVIO also demonstrated significant efficacy in skin healing. Long-term studies show that 91% of patients with PN achieved lasting skin healing after nearly 2 years on NEMLUVIO.|| Long-term studies also show that 88% of patients with AD experienced clearer skin with NEMLUVIO combined with TCS/TCI over 2 years of treatment.¶ The images below illustrate this improvement, showing real patient results from baseline to Week 16.3,4

At Week 16, 38% of patients with PN taking NEMLUVIO achieved clear (IGA 0) or almost clear (IGA 1) skin vs 11% with placebo.1

At Week 16, 36% of patients with AD taking NEMLUVIO + TCS/TCI achieved clear (IGA 0) or almost clear (IGA 1) skin vs 25% with placebo + TCS/TCI.1
The most common adverse reactions (incidence ≥1%) include headache (including migraine), arthralgia, urticaria, and myalgia for AD, and headache, dermatitis atopic, eczema, and eczema nummular for PN. With a favorable safety profile, NEMLUVIO requires no preliminary lab evaluations or ongoing lab monitoring. For Important Safety Information, please see the end of this email.1
Now, as the fastest growing biologic for AD for ages 12 years and older,# NEMLUVIO stands out as the only biologic approved for PN and AD, with Q4W dosing from the start and the possibility for Q8W dosing in AD. NEMLUVIO offers convenience and flexibility. Patients may require as few as 13 doses per year compared to 26 with dupilumab.1,10**
Ready to learn more about NEMLUVIO? Visit www.nemluviohcp.com for details.
OLYMPIA AND ARCADIA STUDY DESIGNS
OLYMPIA 1 and 2 were randomized, placebo-controlled, pivotal Phase 3 trials that evaluated NEMLUVIO in 560 adults aged ≥18 years who had moderate-to-severe PN for ≥6 months. Primary endpoints were the proportion of patients achieving a ≥4-point improvement from baseline in PP-NRS score and an IGA of 0 or 1 and a 2-point improvement from baseline at Week 16. PAS item 5b was a secondary endpoint.1,11,12
The OLYMPIA LTE is an ongoing, prospective, multicenter, single-arm, open-label study up to 184 weeks designed to assess the long-term safety and efficacy of NEMLUVIO in 508 patients.4
ARCADIA 1 and 2 were identically designed, multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase 3 studies that evaluated NEMLUVIO in adults and adolescents aged ≥12 years with moderate-to-severe AD not adequately controlled with TCS/TCI. Co-primary endpoints were the proportion of patients achieving an IGA 0 or 1 and a 2-point improvement from baseline and an EASI-75 score of ≥75% improvement from baseline at Week 16. Select key secondary endpoints included ≥4-point improvement on the PP-NRS scale from baseline.1
The ARCADIA LTE is an ongoing prospective, multicenter, open-label study up to 200 weeks that assesses the long-term safety and efficacy of NEMLUVIO in 1751 patients.3
*PP-NRS response was achieved at 48 hours (AD: 10.7% with NEMLUVIO + TCS/TCI vs 2.9% with placebo + TCS/TCI; PN: 17.2% vs 3.7% with placebo). Data from pooled post-hoc analysis of daily PP-NRS improvement reported in Phase 3 clinical studies (ARCADIA 1 and 2, OLYMPIA 1 and 2). PP-NRS response defined as a ≥4-point improvement from baseline. No conclusions regarding efficacy should be made based on these results.2
†Data from OLYMPIA 2; in OLYMPIA 1, 56% of patients taking NEMLUVIO achieved significant itch relief by Week 16 vs 16% taking placebo. PP-NRS response defined as ≥4-point improvement from baseline.1
‡Data shown are for patients in the nemolizumab group without prior nemolizumab exposure. The rate was 92% among patients with previous nemolizumab experience and in the overall nemolizumab‑treated population. Data based on interim analysis in nemolizumab-naive patients with PP-NRS ≥4 improvement at Week 100 of OLYMPIA LTE. No imputations for missing data.4
§Data shown are for patients in the nemolizumab group without prior nemolizumab exposure. The rate was 87% among patients with previous nemolizumab experience and in the overall nemolizumab‑treated population. Observed cases of a ≥4-point improvement in the Pruritus VAS component of SCORAD in ARCADIA LTE interim analysis at Week 104 in nemolizumab-naive patients.3
||Data based on PAS item 5b (≥75% healed pruriginous lesions) interim analysis of nemolizumab-naive patients at Week 100 of the OLYMPIA LTE. No imputations for missing data.4
¶EASl-75 data for nemolizumab-naive patients reaching 104 weeks at interim analysis of ARCADIA LTE.3
#Measuring JAN-OCT 2025 compounded growth rate using IQVIA NPA data with indication factoring for both NEMLUVIO (SP & HUB data) and competitors (IQVIA LAAD).
**For pediatric patients weighing ≥66 lbs, dupilumab may be dosed Q4W.10
EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; IL-31RA=interleukin-31 receptor alpha; LTE=long-term extension; PAS=Prurigo Activity Score; PP-NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks; Q8W=every 8 weeks; SCORAD=Scoring Atopic Dermatitis; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid; VAS=Visual Analog Scale.
IMPORTANT SAFETY INFORMATION
INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:
- the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
- the treatment of adults with prurigo nodularis.
CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.
WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.
ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:
- Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia.
- Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular.
USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.
Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.
Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.
Please see full Prescribing Information including Patient Information.
References:
- NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.
- Ständer S, Elmariah SB, Kwatra SG, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. J Eur Acad Dermatol Venereol. 2025;00:1-9. doi:10.1111/jdv.70250
- Augustin M, Tauber M, Sidbury R, et al. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J Eur Acad Dermatol Venereol. 2025;00:1-15. doi:10.1111/jdv.70080
- Legat FJ, Kwatra SG, Reich A, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol. 2025;00:1-13. doi:10.1111/jdv.70266
- Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097
- Mousa A, Bakhiet M. Role of cytokine signaling during nervous system development. Int J Mol Sci. 2013;14(7):13931-13957. doi:10.3390/ijms140713931
- Feld M, Garcia R, Buddenkotte J, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500-508.e24. doi:10.1016/j.jaci.2016.02.020
- Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol. 2019;10:1383. doi:10.3389/fimmu.2019.01383
- Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.203065 [OLYMPIA 2]; September 2023.
- DUPIXENT Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc.; 2024.
- Kwatra SG, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579-1589.
- Kwatra SG, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579-1589. Supplementary appendix.
US-NLV-2600026 02/26